Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (SG:T14)

SGX:T14

T14

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S

RESEARCH TOOLSreports

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (T14) Price & Analysis

8 Followers

T14 Stock Chart & Stats

$3.26

-$0.01(-0.48%)

At close: Jan 08 4:00 PM EST

$3.26

-$0.01(-0.48%)

Day’s Range― - ―

52-Week Range$2.37 - $3.75

Previous CloseN/A

Volume125.30K

Average Volume (3M)117.62K

Market Cap

$3.77B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)7.9

Beta0.22

Next Earnings

Aug 19, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield5.12%

Share Statistics

EPS (TTM)0.26

Shares Outstanding200,000,000

10 Day Avg. Volume127,120

30 Day Avg. Volume117,623

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S News

Tianjin Da Ren Tang Shareholders Back All FY2025 AGM Resolutions

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) has provided an announcement. Shareholders of Tianjin...

11d ago

Tianjin Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy Proceedings

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) has issued an announcement. Tianjin Pharmaceutical Da...

12d ago

Tianjin Da Ren Tang Schedules Online Briefing on FY2025 and Q1 2026 Results

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) just unveiled an update. Tianjin Pharmaceutical Da...

12d ago

Tianjin Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy

An update from Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) is now available. Tianjin...

1M ago

Tianjin Pharmaceutical Da Ren Tang Board Clears Q1 Results and Ends Equity Custody Deal

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) has shared an announcement. Tianjin Pharmaceutical Da...

2M ago

Da Ren Tang refines TCM focus, adopts 2026 quality and AI-driven growth plan

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) has provided an update. Tianjin Pharmaceutical Da...

2M ago

Tianjin Pharmaceutical Da Ren Tang Reports No New Impact From Subsidiary Bankruptcy

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) has shared an announcement. Tianjin Pharmaceutical Da...

4M ago

Controlling Shareholder of Tianjin Pharmaceutical Da Ren Tang Lifts Stake via S-Share Purchase

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) has shared an announcement. Tianjin Pharmaceutical Da...

4M ago

Tianjin Da Ren Tang Reports No New Impact From Subsidiary’s Bankruptcy Liquidation

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) just unveiled an announcement. Tianjin Pharmaceutical Da...

4M ago

Tianjin Pharmaceutical Da Ren Tang Holds Second FY2025 Extraordinary General Meeting in Hybrid Format

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S ( ($DE:2TZ) ) has provided an update. Tianjin Pharmaceutical Da...

5M ago

T14 FAQ

What was Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price range in the past 12 months?

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S lowest share price was $2.37 and its highest was $3.75 in the past 12 months.

What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap?

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap is $3.77B.

When is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date?

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date is Aug 19, 2026 which is in 66 days.

How were Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s earnings last quarter?

Currently, no data Available

Is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S overvalued?

According to Wall Street analysts Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pay dividends?

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pays a Annually dividend of $0.35 which represents an annual dividend yield of 5.12%. See more information on Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S dividends here

What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate?

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S have?

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S has 200,000,000 shares outstanding.

What happened to Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S?

Currently, no hedge funds are holding shares in SG:T14

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S

Tianjin Zhong Xin Pharmaceutical Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.